Rheumatology Leaders Concerned CVS/Aetna Merger Will Hinder Efforts to Lower Drug Costs September 06, 2019 Statement from: Angus Worthing, MD, ACR Government Affairs Committee Chair As policy makers and healthcare professionals continue to work together on ways to lower drug costs for patients, the ACR has worked to educate leaders in Congress about the lack of transparency from pharmacy benefits managers (PBMs) on the savings they are negotiating and whether those are being passed to patients. Though PBMs claim to use their position to negotiate lower drug prices, there has been no proof that rebates have been used to reduce the burden on patients and the healthcare system at large. In recent years, several states have enacted legislation to hold PBMs accountable and crack down on secretive practices that drive up costs for consumers. State legislation has included gag clause bans, restrictions on claw-back provisions in PBM-insurer contracts, licensure of PBMs in states where they operate, and provisions that protect community pharmacies from unfair PBM auditing practices. These are positive developments, but without the full disclosure of rebates and discounts it is not possible to determine how the rebate system impacts drug prices and patient costs. The ACR is concerned that the federal district court’s recent decision to approve the merger of CVS Health Corporation and Aetna hinders progress that has been made towards creating transparency and will make it easier for costs savings to remain secret. We hope that regulators will now actively watch the conduct of the merged company to ensure patients are protected. Media Contact: Jocelyn Givensjgivens@rheumatology.org404-929-4810 ###The American College of Rheumatology (ACR) is the nation's leading medical association for the rheumatology community and represents more than 7,700 U.S. rheumatologists and rheumatology health professionals. As an ethically driven, professional membership organization, the ACR is committed to improving healthcare for Americans living with rheumatic diseases and advocates for policies and reforms that will ensure safe, effective, affordable and accessible rheumatology care.